ストックスクリーナーアプリを入手
60.21
0.82%
-0.56
前日終値:
$60.77
開ける：
$60.94
24時間の取引高:
2.20M
Relative Volume:
0.16
時価総額：
$122.57B
収益：
$48.19B
当期純損益:
$7.06B
株価収益率:
17.41
EPS:
3.4587
ネットキャッシュフロー:
$15.30B
1週間 パフォーマンス:
+7.65%
1か月 パフォーマンス:
+7.90%
6か月 パフォーマンス:
+31.17%
1年 パフォーマンス:
+8.54%
1日の値動き範囲:
$60.19
$61.45
1週間の範囲:
$56.43
$62.05
52週間の値動き範囲:
$42.52
$63.33
Bristol Myers Squibb Co Stock (BMY) Company Profile
名前
Bristol Myers Squibb Co
セクター
電話
(609) 252-4621
住所
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, NVS, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
60.21 | 123.71B | 48.19B | 7.06B | 15.30B | 3.4587 |
|
LLY
Lilly Eli Co
|
1,036.13 | 935.00B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
238.39 | 574.95B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
223.88 | 394.59B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
NVS
Novartis Ag Adr
|
157.93 | 299.68B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
193.75 | 291.47B | 58.07B | 9.40B | 9.87B | 3.0115 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | アップグレード | UBS | Neutral → Buy |
| 2025-12-15 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-12-12 | アップグレード | Guggenheim | Neutral → Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Perform |
| 2025-08-05 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | 開始されました | Cantor Fitzgerald | Neutral |
| 2025-04-22 | 開始されました | Piper Sandler | Overweight |
| 2024-12-16 | アップグレード | Jefferies | Hold → Buy |
| 2024-12-10 | 再開されました | BofA Securities | Neutral |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-13 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | ダウングレード | Citigroup | Buy → Neutral |
| 2024-10-17 | 開始されました | Bernstein | Mkt Perform |
| 2024-07-29 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2024-03-11 | ダウングレード | Societe Generale | Buy → Hold |
| 2024-02-06 | ダウングレード | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-11-15 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | アップグレード | HSBC Securities | Reduce → Hold |
| 2023-10-27 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | 再開されました | UBS | Neutral |
| 2023-07-14 | 開始されました | HSBC Securities | Reduce |
| 2023-07-10 | 開始されました | SVB Securities | Market Perform |
| 2023-06-28 | 開始されました | Daiwa Securities | Outperform |
| 2023-03-06 | 開始されました | Jefferies | Hold |
| 2023-01-17 | 開始されました | Cantor Fitzgerald | Overweight |
| 2022-11-18 | 開始されました | Credit Suisse | Neutral |
| 2022-10-10 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-09-14 | ダウングレード | Berenberg | Buy → Hold |
| 2022-06-03 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | 再開されました | Morgan Stanley | Underweight |
| 2021-12-17 | 開始されました | Goldman | Buy |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
| 2021-11-01 | ダウングレード | Argus | Buy → Hold |
| 2021-07-27 | 再開されました | Truist | Buy |
| 2021-04-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | アップグレード | Truist | Hold → Buy |
| 2020-11-16 | アップグレード | Societe Generale | Hold → Buy |
| 2020-11-10 | 再開されました | Bernstein | Mkt Perform |
| 2020-11-06 | ダウングレード | Gabelli & Co | Buy → Hold |
| 2020-10-19 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-09-29 | 開始されました | Berenberg | Buy |
| 2020-07-28 | 開始されました | Raymond James | Outperform |
| 2020-04-02 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | ダウングレード | Societe Generale | Buy → Hold |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-06 | 再開されました | Citigroup | Buy |
| 2019-12-13 | アップグレード | Argus | Hold → Buy |
| 2019-11-22 | 再開されました | Morgan Stanley | Equal-Weight |
| 2019-10-17 | 再開されました | BofA/Merrill | Buy |
| 2019-08-14 | アップグレード | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | 開始されました | Goldman | Buy |
| 2019-05-20 | ダウングレード | Argus | Buy → Hold |
| 2019-05-03 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-05-03 | 再開されました | JP Morgan | Overweight |
| 2019-01-15 | アップグレード | Societe Generale | Sell → Buy |
| 2018-10-22 | ダウングレード | Citigroup | Buy → Neutral |
すべてを表示
Bristol Myers Squibb Co (BMY) 最新ニュース
Bristol-Myers Squibb stock rating reiterated by Bernstein at Market Perform - Investing.com India
Bristol-Myers Squibb: Solid Near-Term Execution and 2026 EPS Boost from Eliquis, but Limited Long-Term Visibility Supports Hold Rating - TipRanks
Assessing Bristol Myers Squibb (BMY) Valuation After Earnings Beat And Pipeline Optimism - Yahoo Finance UK
Idiopathic Pulmonary Fibrosis Clinical Trials & Pipeline Overview: Insights into 80+ Leading Companies and 100+ Novel Treatments | DelveInsight - GlobeNewswire Inc.
Guggenheim Raises its Price Target on Bristol-Myers Squibb Company (BMY) to $72 and Reiterates a Buy Rating - Finviz
Evinova and Bristol Myers Squibb Forge Strategic Collaboration to Optimize Clinical Development with Artificial Intelligence - Yahoo Finance Singapore
Bristol-Myers Squibb Stock Is On Sale: Smart Buy Or Value Trap You’ll Regret? - AD HOC NEWS
Bristol-Myers Squibb Stock: Dividend Giant Under Pressure or Deep-Value Setup? - AD HOC NEWS
Jim Cramer Discusses Bristol Myers's (BMY) Cobenfy Drug - Finviz
Jim Cramer Discusses Bristol Myers’s (BMY) Cobenfy Drug - Insider Monkey
Birmingham Capital Management Co. Inc. AL Reduces Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Returns To US$7.1b Trailing Profit Challenging Bearish Narratives - simplywall.st
Bristol-Myers Squibb stock price target raised to $72 by Guggenheim - Investing.com UK
Bristol-Myers Squibb stock price target raised to $60 by Wells Fargo - Investing.com UK
Bristol-Myers Squibb: A Dividend Gem With Hidden Upside In 2026 (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb (NYSE:BMY) Given New $64.00 Price Target at Citigroup - MarketBeat
Bristol-Myers Squibb stock price target raised to $72 by Guggenheim By Investing.com - Investing.com India
Bristol-Myers Squibb Co (NYSE:BMY) Tops Estimates - FXDailyReport.Com
Bristol-Myers Squibb Co (BMY) Stock Price Up 3.76% on Feb 6 - GuruFocus
Wells Fargo Raises Price Target for Bristol-Myers Squibb (BMY) | BMY Stock News - GuruFocus
Bristol-Myers Squibb Company (NYSE:BMY) Q4 2025 Earnings Call Transcript - Insider Monkey
Bristol-Myers Squibb Co. (BMY) PT Raised to $72 at Guggenheim - StreetInsider
BMS reports flat revenue growth for full-year 2025 - Pharmaceutical Technology
BMY Q4 Deep Dive: Growth Portfolio Offsets Legacy Pressure, Pipeline Readouts in Focus - Finviz
Bristol Myers Squibb stock gets positive readthrough from Bayer stroke data - Investing.com
Bristol-Myers Squibb (BMY) Exceeds Q4 Earnings Expectations - GuruFocus
Bristol-Myers Squibb (BMY) Surpasses Q4 Expectations, Sets Stron - GuruFocus
Bristol-Myers Squibb (BMY) Reports Strong Q4, Projects Robust Gr - GuruFocus
Why Bristol Myers Squibb Stock Topped the Market Today - Yahoo Finance
Bristol Myers (BMY) Maintains Positive Outlook Amid Stroke Treat - GuruFocus
Reiterating Buy on Bristol-Myers Squibb: Milvexian’s Validated FXIa Mechanism and Underappreciated Stroke Prevention Upside Support $65 Target - TipRanks
Bristol-Myers Squibb Co (BMY) Q4 2025 Earnings Call Highlights: Strong Growth in New Products ... By GuruFocus - Investing.com Canada
Bristol's Portfolio of Newer Therapies and Strong Late-Stage Pipeline Support a Wide Moat - morningstar.com
Bristol-Myers Squibb Co (BMY) Q4 2025 Earnings Call Highlights: - GuruFocus
Bristol-Myers Squibb (BMY) Surpasses Q4 Expectations and Raises Dividend - GuruFocus
Bristol Myers Earnings Reveal Struggling Legacy Drug Business. Why the Stock Is Rising. - Barron's
We're increasing our price target on Bristol Myers after earnings and guidance top forecasts - CNBC
BMS Beats Again Despite Eliquis and Cobenfy Disappointments - BioSpace
Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates - Finviz
Bristol Myers Stock Rises on Earnings. This Drug Portfolio Continues to Be a Drag. - Barron's
Bristol-Myers Squibb Q4 2025 slides: Growth portfolio offsets legacy declines - Investing.com
Bristol Myers posts modest Q4 growth, outlines cautious outlook - The Pharma Letter
Earnings call transcript: Bristol-Myers Squibb beats Q4 2025 forecasts By Investing.com - Investing.com India
Earnings call transcript: Bristol-Myers Squibb beats Q4 2025 forecasts - Investing.com
Bristol’s Outlook Tops Views as New Drugs Gain Momentum - bloomberg.com
Bristol Myers Squibb (NYSE:BMY) Issues FY 2026 Earnings Guidance - MarketBeat
Bristol Myers earnings beat amid blood thinner, cancer immunotherapy strength - Investing.com India
Bristol-Myers Squibb (NYSE:BMY) Reports Strong Q4 CY2025 - Finviz
Bristol Myers Squibb Co (NYSE:BMY) Beats Q4 2025 Earnings Estimates and Provides Strong 2026 Outlook - Chartmill
Bristol Myers: Q4 Earnings Snapshot - kens5.com
Bristol Myers earnings beat estimates amid cancer immunotherapy drug strength - Investing.com
Bristol Myers Squibb Co (BMY) 財務データ
収益
当期純利益
現金流量
EPS
1.35%
1.21%
大文字化:
|
ボリューム (24 時間):